March-April 2017


Glioma Imaging in the Era of Antiangiogenic Therapy

Farid pic

Nikdokht Farid

In the rapidly evolving landscape of postsurgical, postradiation therapeutic strategies for patients with glioblastoma (GBM), including cytotoxic chemotherapy, antiangiogenic therapy, and immune therapy, bevacizumab has been established as a primary therapeutic option for recurrent GBM1,2 and has also shown substantial promise in the setting of newly diagnosed GBM.1,3  As a recombinant humanized … more »


Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas

Daniels pic

Dianne Daniels

Our group has previously introduced delayed-contrast MR imaging for calculating treatment-response-assessment maps (TRAMs) in patients with brain tumors undergoing standard treatments, providing a clear separation between an active tumor and treatment effects.1,2 Following this application of the TRAMs methodology to aid patient management and decision-making in patients with newly diagnosed high-grade glioma … more »


Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy

Kovanlikaya pic

Ilhami Kovanlikaya

Glioblastoma (GBM) is the most common aggressive primary brain tumor. Despite an aggressive multimodal treatment approach that includes surgical resection and chemoradiation, median survival is limited to approximately 14 months.1

Until recently, there was no standard treatment for recurrent disease after combined chemotherapy and radiation treatment. Between 1998 and 2014, there were 78 … more »


Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls

Pope pic

Whitney B. Pope

We published the first paper on bevacizumab-treated glioma over a decade ago and have since seen bevacizumab become an increasingly common, though controversial (as it does not seem to prolong survival), treatment for patients with glioma and other brain tumors. Given the large number of bevacizumab-treated patients in our neuro-oncology clinic, … more »


Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma

Ellingson pic

Benjamin M. Ellingson

High-grade gliomas including glioblastoma (GBM) have a terrible prognosis and survival has not changed appreciably in the last few decades. As a consequence of myriad failed trials, drug discovery in GBM has diminished extensively. Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor A (VEGFA), is one of only 3 … more »